Hemenway Trust Co LLC Sells 4,014 Shares of Gilead Sciences, Inc. (GILD)
Hemenway Trust Co LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,659 shares of the biopharmaceutical company’s stock after selling 4,014 shares during the period. Hemenway Trust Co LLC’s holdings in Gilead Sciences were worth $2,053,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capital International Investors grew its position in Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after buying an additional 5,205,983 shares in the last quarter. Sanders Capital LLC grew its position in Gilead Sciences by 102.9% during the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock worth $757,119,000 after buying an additional 5,026,015 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its position in Gilead Sciences by 230.0% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after buying an additional 3,434,450 shares in the last quarter. Renaissance Technologies LLC grew its position in Gilead Sciences by 35.0% during the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after buying an additional 2,700,600 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in Gilead Sciences by 84.7% during the third quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock worth $446,197,000 after buying an additional 2,524,657 shares in the last quarter. Institutional investors own 77.96% of the company’s stock.
A number of equities research analysts recently issued reports on GILD shares. Maxim Group set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, December 11th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target on the stock. in a research report on Wednesday, January 17th. Jefferies Group raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $81.19 to $93.00 in a research report on Friday, January 26th. Finally, Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their target price for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $88.61.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the prior year, the company earned $2.70 EPS. Gilead Sciences’s revenue was down 18.7% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.79%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 59.77%.
In other news, Director John Francis Cogan sold 5,833 shares of the stock in a transaction on Monday, March 12th. The stock was sold at an average price of $80.93, for a total value of $472,064.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders sold a total of 430,268 shares of company stock valued at $34,074,395 over the last quarter. 1.30% of the stock is owned by corporate insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.